title: Hepatitis B: treatment choice and monitoring for response and resistance.
abstract: Despite effective preventive primary prevention with vaccination, many people remain infected with hepatitis B virus (HBV) and suffer from its complications. Effective treatments such as interferon-based regimens and oral nucleoside/nucleotides have been developed over the last 30 years, but they are not perfect. Each of the treatments has its own merits, but none can eradicate HBV from the host. As a result, regular monitoring of the response during treatment and after treatment is required. The choice and monitoring of selected treatments, new potential therapeutic agents, and treatment options for drug resistance are discussed in this review.
authors.affiliation: a Department of Medicine, Queen Mary Hospital , University of Hong Kong , Hong Kong , China.
authors.forename: Sze-Hang Kevin
authors.initials: SH
authors.lastname: Liu
authors.affiliation: a Department of Medicine, Queen Mary Hospital , University of Hong Kong , Hong Kong , China.|b State Key Laboratory for Liver Research , University of Hong Kong, Queen Mary Hospital , Hong Kong , China.
authors.forename: Wai-Kay
authors.initials: WK
authors.lastname: Seto
authors.affiliation: a Department of Medicine, Queen Mary Hospital , University of Hong Kong , Hong Kong , China.|b State Key Laboratory for Liver Research , University of Hong Kong, Queen Mary Hospital , Hong Kong , China.
authors.forename: Ching-Lung
authors.initials: CL
authors.lastname: Lai
authors.affiliation: a Department of Medicine, Queen Mary Hospital , University of Hong Kong , Hong Kong , China.|b State Key Laboratory for Liver Research , University of Hong Kong, Queen Mary Hospital , Hong Kong , China.
authors.forename: Man-Fung
authors.initials: MF
authors.lastname: Yuen
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D006801:Humans; D018579:Patient Selection; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents
keywords: ARC-520; Myrcludex B; entecavir; hepatitis B virus; interferon-alfa; monitor; tenofovir; treatment